# A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Source: https://onco.cc/trials/nct05941507/  
OnCo record `nct05941507` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LCB84 in advanced solid tumours, run by LigaChem Biosciences, Inc., now recruiting.

## Summary

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05941507 by LigaChem Biosciences, Inc., with 300 participants planned, started 2023-10-05 and due to reach its primary completion in 2027-01. Interventions recorded: LCB84 and Anti-PD-1 monoclonal antibody.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05941507
- Phase: 1/2
- Setting: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors
- Sponsor: LigaChem Biosciences, Inc.
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT05941507: https://clinicaltrials.gov/study/NCT05941507

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [LCB84](https://onco.cc/drugs/lcb84/)
- companies: [LigaChem Biosciences](https://onco.cc/companies/ligachem-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05941507.json